Nevro Corp (NYSE:NVRO) Director Wilfred E. Jaeger sold 160,542 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $80.77, for a total value of $12,966,977.34. Following the transaction, the director now owns 1,518 shares in the company, valued at approximately $122,608.86. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Nevro Corp (NVRO) traded down $0.13 on Wednesday, hitting $86.68. The stock had a trading volume of 268,174 shares, compared to its average volume of 373,781. Nevro Corp has a one year low of $65.00 and a one year high of $97.70. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.91 and a current ratio of 7.61. The company has a market cap of $2,590.45, a price-to-earnings ratio of -68.79 and a beta of -0.51.
Nevro (NYSE:NVRO) last issued its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). Nevro had a negative net margin of 11.22% and a negative return on equity of 15.01%. The business had revenue of $97.96 million during the quarter, compared to the consensus estimate of $96.87 million. During the same quarter in the previous year, the business posted ($0.34) EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. equities analysts expect that Nevro Corp will post -0.76 earnings per share for the current fiscal year.
A number of equities analysts have commented on NVRO shares. BidaskClub lowered Nevro from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. BMO Capital Markets restated a “buy” rating and set a $100.00 price objective on shares of Nevro in a research note on Thursday, December 14th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Nevro has an average rating of “Hold” and an average price target of $99.25.
Hedge funds have recently modified their holdings of the stock. Hershey Trust Co. bought a new stake in Nevro during the 4th quarter worth $119,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Nevro during the 3rd quarter worth $211,000. Public Employees Retirement Association of Colorado bought a new stake in Nevro during the 4th quarter worth $160,000. Glenmede Trust Co. NA bought a new stake in Nevro during the 4th quarter worth $237,000. Finally, HBK Investments L P bought a new stake in Nevro during the 4th quarter worth $255,000.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.